The ecosystem integrates two diagnostic levels into one patient record to help physicians personalize sleep apnea diagnostics and monitoring.
RT’s Three Key Takeaways:
- Dual Diagnostic Tiers: The platform combines Wesper Lab for high-fidelity respiratory analysis and Wesper Lite for high-volume screening and remote patient monitoring.
- Streamlined Clinical Workflow: Both testing levels utilize a single patient record and interpretation pipeline, allowing for study escalation without re-onboarding patients.
- Scientific Validation: Research presented at Sleep 2026 supports the platform’s artificial intelligence-driven detection of central sleep apnea and its ability to identify specific phenotypes in obese patients.
Wesper, a developer of home sleep apnea testing (HSAT), introduced its multi-tier sleep diagnostic ecosystem at Sleep 2026, the annual meeting of the Associated Professional Sleep Societies (APSS). The platform integrates two diagnostic pathways, Wesper Lab and Wesper Lite, into a single patient record and interpretation pipeline.
The system is designed to provide clinicians with flexibility as demand for sleep testing increases. Wesper Lab is a high-fidelity, respiratory-based test designed for detailed analysis and follow-up, featuring cannula-free airflow, positional analysis, and central apnea detection. Wesper Lite is an optical sensor-based test using photoplethysmography (PPG) for general diagnostics, high-volume screening, and remote patient monitoring.
“Sleep apnea is a complicated condition that presents uniquely in every patient, but existing sleep testing has often been approached as one-size-fits-all,” said Amir Reuveny, chief executive officer and founder of Wesper, in a news release. “With Wesper Lab and Wesper Lite on one ecosystem, physicians can choose the right test for each patient and follow that patient through diagnosis, treatment, and ongoing monitoring on a single record. That is what personalized sleep testing—and ultimately personalized care, looks like.”
The platform allows a Wesper Lite study to be escalated to a Wesper Lab study without the need to re-onboard the patient. According to the company, Wesper Lite provides diagnostics validated at a 96% correlation to the apnea-hypopnea index (AHI) found in polysomnography (PSG).
Wesper also presented three research posters at the conference to support the clinical depth of the ecosystem. The research included data on provider-tuned autoscoring, artificial intelligence-driven central sleep apnea detection validated against PSG, and an underrecognized positional obstructive sleep apnea (OSA) phenotype in obese patients that standard AHI may miss.
